Parasitic Helminthiasis Infectious Disease

Categories: Gastrointestinal diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Parasitic Helminthiasis Infectious Disease

MalaCards integrated aliases for Parasitic Helminthiasis Infectious Disease:

Name: Parasitic Helminthiasis Infectious Disease 12 15
Helminthiasis 12 73 20 54 44 17 70
Intestinal Helminthiasis 20 70
Helminth Infections 15
Helminth Infection 12
Worm Infections 20
Worm Infection 12
Helminthosis 12


External Ids:

Disease Ontology 12 DOID:883
ICD9CM 34 120-129.99
MeSH 44 D006373
NCIt 50 C84751
SNOMED-CT 67 187518006
ICD10 32 B82.0 B83.9
UMLS 70 C0018889 C0348287

Summaries for Parasitic Helminthiasis Infectious Disease

Disease Ontology : 12 A parasitic infectious disease that occurs when part of the body is infested with parasitic worms such as cestodes, nematodes and trematodes.

MalaCards based summary : Parasitic Helminthiasis Infectious Disease, also known as helminthiasis, is related to paragonimiasis and angiostrongyliasis. An important gene associated with Parasitic Helminthiasis Infectious Disease is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Praziquantel and Artemether have been mentioned in the context of this disorder. Affiliated tissues include skin, whole blood and lymph node, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 73 Helminthiasis, also known as worm infection, is any macroparasitic disease of humans and other animals... more...

Related Diseases for Parasitic Helminthiasis Infectious Disease

Diseases related to Parasitic Helminthiasis Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 651)
# Related Disease Score Top Affiliating Genes
1 paragonimiasis 32.6 RNASE3 MT-CO1 IL5 IL13
2 angiostrongyliasis 32.6 MT-CO1 IL5 IL4 IL13
3 baylisascariasis 32.6 MT-ND1 MT-CO1 IL10
4 diphyllobothriasis 32.6 MT-ND1 MT-CO1
5 ascaris lumbricoides infection 32.6 TSLP SERPINA3 IL5 IL13
6 fascioliasis 32.6 MT-ND1 MT-CO1 IL10
7 coenurosis 32.6 MT-ND1 MT-CO1
8 toxocariasis 32.6 RNASE3 IL5 IL4 IL13 IL10
9 strongyloidiasis 32.5 MT-CO1 IL5 IL4 IL13 CD4
10 sparganosis 32.5 MT-ND1 MT-CO1
11 trichuriasis 32.5 SERPINA3 IL9 IL13 IL10 CCR6
12 enterobiasis 32.5 MT-CO1 IL4
13 echinococcosis 32.4 RNASE3 MT-ND1 MT-CO1 IL5 IL17A IL10
14 taeniasis 32.4 MT-ND1 MT-CO1 IL5 IL4 IL13 IL10
15 trichinosis 32.2 TSLP IL9 IL5 IL4 IL17A IL13
16 schistosomiasis 32.1 STAT6 RNASE3 IL9 IL5 IL4 IL33
17 hypereosinophilic syndrome 31.4 RNASE3 IL9 IL5 IL4 IL13
18 cytokine deficiency 31.2 IL9 IL5 IL13
19 ige responsiveness, atopic 31.1 RNASE3 IL5 IL4 IL13 IL10
20 onchocerciasis 31.0 SERPINA3 RNASE3 IL5 IL4 IL13
21 giardiasis 31.0 IL17A IL10 CD4
22 loiasis 31.0 IL9 IL5 IL4 IL13 IL10 CD4
23 filarial elephantiasis 30.9 MT-CO1 IL9 IL5 IL4 IL13 IL10
24 mastocytosis 30.9 IL9 IL4 IL13
25 colitis 30.8 IL4 IL17A IL13 IL10 ICOSLG CD4
26 cysticercosis 30.8 MT-ND1 MT-CO1 IL5 IL4 IL10 CD4
27 pulmonary eosinophilia 30.8 RNASE3 IL5 IL4 IL13
28 ulcerative colitis 30.7 IL4 IL17A IL13 IL10 CCR6
29 cutaneous leishmaniasis 30.7 IL5 IL4 IL17A IL13 IL10
30 leishmaniasis 30.7 IL5 IL4 IL17A IL13 IL10
31 eosinophilic pneumonia 30.7 RNASE3 IL5 IL4 IL33 IL13
32 tetanus 30.6 IL9 IL5 IL4 IL13 IL10
33 autoimmune disease 30.6 IL9 IL5 IL4 IL17A IL13 IL10
34 severe combined immunodeficiency 30.6 STAT6 IL9 IL4 IL17A IL13 IL10
35 gastroenteritis 30.6 TSLP RNASE3 IL5 IL4 IL33 IL10
36 bacterial infectious disease 30.6 SERPINA3 IL17A IL10 ICOSLG H2AC18 CD4
37 scabies 30.6 IL10 CD4 CCR6
38 deficiency anemia 30.6 SERPINA3 ICOSLG H2AC18 CD4 CCR6
39 disease by infectious agent 30.5 SIGLEC5 SERPINA3 MIR21 IL4 IL17A IL10
40 poliomyelitis 30.5 IL4 IL10 CD4
41 dysentery 30.5 IL10 H2AC18 CD4 CCR6
42 crohn's disease 30.5 IL4 IL17A IL13 IL10 ICOSLG CD4
43 allergic disease 30.5 TSLP RNASE3 IL9 IL5 IL4 IL33
44 pneumonia 30.5 IL5 IL4 IL17A IL13 IL10
45 trachoma 30.5 SERPINA3 IL4 IL17A IL10
46 allergic asthma 30.5 TSLP STAT6 RNASE3 IL9 IL5 IL4
47 rubella 30.4 IL5 IL4 IL10
48 otitis media 30.4 RNASE3 IL5 IL4 IL17A IL10
49 trypanosomiasis 30.4 IL9 IL4 IL10 H2AC18
50 conjunctivitis 30.4 RNASE3 IL5 IL4 IL33 IL13 IL10

Graphical network of the top 20 diseases related to Parasitic Helminthiasis Infectious Disease:

Diseases related to Parasitic Helminthiasis Infectious Disease

Symptoms & Phenotypes for Parasitic Helminthiasis Infectious Disease

MGI Mouse Phenotypes related to Parasitic Helminthiasis Infectious Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 CCR6 CD4 FAM53B IL10 IL13 IL17A
2 homeostasis/metabolism MP:0005376 10.1 CCR6 CD4 FAM53B IL10 IL13 IL17A
3 digestive/alimentary MP:0005381 10.02 CD4 IL10 IL13 IL17A IL33 IL4
4 immune system MP:0005387 9.93 CCR6 CD4 IL10 IL13 IL17A IL33
5 integument MP:0010771 9.61 CD4 IL10 IL13 IL17A IL33 IL4
6 respiratory system MP:0005388 9.23 IL10 IL13 IL17A IL33 IL4 IL5

Drugs & Therapeutics for Parasitic Helminthiasis Infectious Disease

Drugs for Parasitic Helminthiasis Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Praziquantel Approved, Investigational, Vet_approved Phase 4 55268-74-1 4891
Artemether Approved Phase 4 71963-77-4 9796294 119380 68911
Lumefantrine Approved Phase 4 82186-77-4 6437380
Sodium citrate Approved, Investigational Phase 4 68-04-2
Piperazine Approved, Vet_approved Phase 4 110-85-0 4837
Ivermectin Approved, Investigational, Vet_approved Phase 4 70288-86-7 6474909
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
Iron Approved Phase 4 7439-89-6 23925 29936
Levamisole Approved, Investigational, Vet_approved, Withdrawn Phase 4 14769-73-4 26879
Ferrous fumarate Approved Phase 4 141-01-5
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
Copper Approved, Investigational Phase 4 7440-50-8 27099
Iodine Approved, Investigational Phase 4 7553-56-2 807
Zinc Approved, Investigational Phase 4 7440-66-6 32051
Mebendazole Approved, Vet_approved Phase 4 31431-39-7 4030
Pyrantel Approved, Vet_approved Phase 4 15686-83-6
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6, 59-43-8 1130
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
Cobalamin Experimental Phase 4 13408-78-1 6857388
Cadexomer iodine Experimental Phase 4 94820-09-4
32 Benzimidazole Experimental, Investigational Phase 4 51-17-2
33 Antimalarials Phase 4
34 Artemisinine Phase 4
35 Artemether, Lumefantrine Drug Combination Phase 4
36 Artemisinins Phase 4
37 Vitamins Phase 4
38 Calciferol Phase 4
39 Citrate Phase 4
40 Piperazine citrate Phase 4
41 DMP 777 Phase 4 157341-41-8
42 Vitamin B9 Phase 4
43 Vitamin B Complex Phase 4
44 Folate Phase 4
45 Vitamin B 12 Phase 4
46 Vitamin B12 Phase 4
47 Immunologic Factors Phase 4
48 Adjuvants, Immunologic Phase 4
49 Nutrients Phase 4
50 Trace Elements Phase 4

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
2 Longitudinal Study of Efficacy of Standard Albendazole Treatment Versus Levamisole/Pyrantel Pamoate on Soil Transmitted Helminth Infections Completed NCT00659997 Phase 4 Albendazole;Levamisole
3 Double-Blind, Placebo-Controlled, Randomized, Prospective, Two-Stage, Two-Arm Study to Evaluate the Efficaciousness and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population Completed NCT02385058 Phase 4 Mebendazole;Quinfamide;Placebo
4 Diarrhea, Malaria, Anemia, and Helminthiasis Prevention Through Household-based Interventions in Rural Western Kenya: the Nyando Integrated Child Health and Education (NICHE) Project Completed NCT01088958 Phase 4
5 The Impact of Different Treatment Strategies on the Transmission Dynamics of Soil-transmitted Helminths: a Cluster Randomised Trial in Kenya Completed NCT02397772 Phase 4 albendazole
6 Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations Completed NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
7 Effect of Intestinal Helminths on Gut Microflora Completed NCT01192802 Phase 4 albendazole;albendazole;albendazole
8 Chengdu Women's and Children's Central Hospital Completed NCT02675140 Phase 4 ZENTEL;ZENTEL and Vitamin A Soft Capsules
9 Human Soil Transmitted Helminths (STH) Resistance to Benzimidazole in School Aged Children Living in Gabon Recruiting NCT04326868 Phase 4 Benzimidazole Anthelmintic
10 Intestinal Microbiome Post-Azythromycin/Albendazole Treatment Withdrawn NCT03032042 Phase 4 Azithromycin;Albendazole;Delayed treatment
11 A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Impact of Anthelmintic Treatment on the Incidence of Diarrheal Disease in School Children in Southern Vietnam Withdrawn NCT02597556 Phase 4 Albendazole;Placebo
12 A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg Chewable Tablet of Mebendazole in the Treatment of Soil-Transmitted Helminth Infections (Ascaris Lumbricoides and Trichuris Trichiura) in Pediatric Subjects Completed NCT02034162 Phase 3 Mebendazole;Placebo
13 Comparative Efficacy of Different Mebendazole Polymorphs in the Treatment of Soil-transmitted Helminth Infections Completed NCT01350271 Phase 3 Mebendazole polymorph A and C 500 mg;Mebendazole polymorph C;Placebo
14 Design and Clinical Evaluation of a School Meal With Deworming Properties Completed NCT02725255 Phase 2, Phase 3 Albendazole
15 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) DeWorm3 Project Recruiting NCT03014167 Phase 3 Albendazole
16 Efficacy and Safety of Moxidectin and Albendazole Compared to Ivermectin and Albendazole Co-administration in Adolescents Infected With Trichuris Trichiura: a Randomized Controlled Trial Not yet recruiting NCT04700423 Phase 2, Phase 3 moxidectin (8 mg) / albendazole (400 mg);ivermectin (200 µg/kg) / albendazole (400 mg);ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL];ivermectin (200 µg/kg);moxidectin (8 mg)
17 Prospective, Parallel-group, Open-label Randomized Controlled Trial of Four Treatment Regimes for Trichuriasis in Pediatric Patients Completed NCT04041453 Phase 2 Ivermectin;Albendazole
18 Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis Active, not recruiting NCT03441893 Phase 1, Phase 2 Nitazoxanide 500Mg Oral Tablet;Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet;Mesalazine 250Mg
19 An Open Comparative Study of the Efficacy of Different Doses of Oxfendazole Compared to Single Dose Albendazole in the Treatment of Trichuris Trichiura Infection in Adults Withdrawn NCT02636803 Phase 2 oxfendazole;albendazole
20 A Phase I Double Blind Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Combination of DNA-HIV-PT123 and AIDSVAX®B/Ein HIV-1-uninfected Adult Participants With or Without Underlying Schistosoma Mansoni Infection Completed NCT02376582 Phase 1
21 A Phase 1 Open Label, Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers Completed NCT03035760 Phase 1 Oxfendazole
22 The Impact of Health Education in Controlling Soil-transmitted Helminthiasis Among Orang Asli Schoolchildren Completed NCT01640626 Phase 1
23 A Single-dose, Two-centre, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Two Kinds of AlbendazoleTablet Formulations in Healthy Chinese Adult Males Completed NCT01755637 Phase 1 Albendazole
24 Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA, Abbott Laboratórios do Brasil Ltda, Brazil) Completed NCT03173742 Phase 1 T1, T2, T3;T1,T3,T2;T2,T1,T3;T2,T3,T1;T3,T1,T2;T3,T2,T1
25 Serum Pharmacokinetic Disposition and Urinary Excretion of Albendazole and Its Metabolites in Non-infected Human Volunteers. Completed NCT03192449 Phase 1 Albendazole.
26 Impact of Helminth Infections During Pregnancy on Humoral Vaccine Immunogenicity in Infants Unknown status NCT02714348
27 Community-based Approach for the Management of Soil-transmitted Helminthiasis in General and Strongyloidiasis in Particular in a Highly Endemic Area Unknown status NCT01308268 Ivermectin + Albendazole
28 Epidemiology of Human Immunodeficiency Virus (HIV-1) and Schistosoma Mansoni Co-infections and Its Impact on Anthelminthic Treatment Outcome Among HIV-1 Infected Individuals in Fishing Communities in Mwanza Region, Northwestern Tanzania. Unknown status NCT01541631 Praziquantel and Albendazole;Praziquantel and Albendazole;Praziquantel and Albendazole
29 Validation of Both Automated Quality Assured Egg Counting System and Molecular Markers for Monitoring the Spread of Anthelmintic Resistance. Completed NCT03465488 Albendazole Pill 400mg (GSK)
30 Immunological Consequences of Helminth and Mycobacterial Coinfection Completed NCT00342017
31 Community-Directed Treatment in the Control of Soil-Transmitted Helminths Among Children Aged 12-59 Months in Mazabuka District of Zambia Completed NCT00349323
32 Assessment of Drug Efficacy of Albendazole Bought on Local Market Against Soil-transmitted Helminth Infections in School Children in Jimma, Ethiopia Completed NCT02420574 albendazole BENDEX;albendazole OVIS
33 Effectiveness of a Post-deworming Education Intervention to Reduce Soil-transmitted Helminth Infections and Absenteeism in Grade 5 School-children in a Community of Extreme Poverty, Peruvian Amazon Completed NCT01085799
34 Evaluation of Dietary Iron Intake, Anemia, and Iron Status Among Men, Women, and Children in Ethiopia Completed NCT04002466
35 The Sero-prevalence and Genetic Study for the Infectious Diseases and Metabolic Syndrome in Solomon Islands Completed NCT01080989
36 The Effect of Schistosome and Soil-transmitted Helminth Infections on Malaria,Infection, Morbidity and Antibody Response Among School and Pre-school Children in Mwanza, Tanzania Completed NCT00347113 Albendazole and praziquantel
37 Efficacy and Nutritional Assessment Following Albendazole and Combined Albendazole/Ivermectin Treatment for Intestinal Helminth Infections in Rural Guatemalan Schoolchildren Completed NCT00207753 albendazole vs. combined albendazole/ivermectin treatment
38 Integrating Community-directed Interventions to Eliminate Neglected Tropical Diseases Caused by Soil-transmitted Helminth Infections and Rabies in Tanzania Completed NCT03667079
39 Impact of Repeated Anthelminthic Treatment on Malaria in School Children: an Individual Randomized, Double-blind, Placebo-controlled Trial in Western Kenya Completed NCT01658774 Albendazole
40 Relative Efficacy of Two Regimens of Ante-helminthic Treatment Completed NCT00367627 Albendazole
41 The Longevity of Trichuris Trichiura Colonization Completed NCT04227925
42 Spillover Effects of Water, Sanitation, and Hygiene Interventions on Child Health Completed NCT02396407
43 Diagnosis of Neglected Tropical Diseases (NTDs) in Patients Presenting With Persistent Digestive Disorders (≥2 Weeks) in Côte d'Ivoire, Indonesia, Mali and Nepal Completed NCT02105714
44 Empiric Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis: A Randomized Controlled Trial in Subjects Co-Infected With Helminths and Leishmania Brasiliensis Completed NCT00469495 Anti-helminthic;meglumine antimony
45 Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Completed NCT00463593
46 Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia Completed NCT00276224 ferrous sulphate (drug)
47 Mucosal and Systemic Immune Modulation From Trichuris Suis in a Self-infected Individual Completed NCT03079700
48 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole (annual);Diethylcarbamazine (annual);Albendazole (semiannual);Diethylcarbamazine (semiannual)
49 Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression Completed NCT00507221 Albendazole;Praziquantel;Current standard of care in Kenya
50 Using Community-Based Volunteers to Reach Non-Enrolled School-Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana Completed NCT00463931

Search NIH Clinical Center for Parasitic Helminthiasis Infectious Disease

Inferred drug relations via UMLS 70 / NDF-RT 51 :

Antihelminthic [EPC]

Cochrane evidence based reviews: helminthiasis

Genetic Tests for Parasitic Helminthiasis Infectious Disease

Anatomical Context for Parasitic Helminthiasis Infectious Disease

MalaCards organs/tissues related to Parasitic Helminthiasis Infectious Disease:

Skin, Whole Blood, Lymph Node, Small Intestine, Colon, Trachea

Publications for Parasitic Helminthiasis Infectious Disease

Articles related to Parasitic Helminthiasis Infectious Disease:

(show top 50) (show all 1619)
# Title Authors PMID Year
Recent advances in the characterization of genetic factors involved in human susceptibility to infection by schistosomiasis. 54 61
19471606 2008
[Toxocariasis in children--difficult clinical problem]. 54 61
18807488 2008
Eosinophil cationic protein as a possible marker of active human Toxocara infection. 54 61
11703226 2001
Hyperimmunoglobulinemia E in the absence of atopy and filarial infection: the Huaorani of Ecuador. 61 54
11191097 2000
Inverse association between skin response to aeroallergens and Schistosoma mansoni infection. 54 61
11060486 2000
Possible relationship between allergic disease and infection by Giardia lamblia. 54 61
8452315 1993
Calcified helminthiasis in a sub-Saharan immigrant patient. 61
32693924 2021
Trichuris trichiura egg extract proteome reveals potential diagnostic targets and immunomodulators. 61
33760829 2021
Soil transmitted helminth infection in primary school children varies with ecozone in the Ngorongoro Conservation Area, Tanzania. 61
33691800 2021
Hookworm infection in infants: a case report and review of literature. 61
33563313 2021
Effectiveness of a community-based integrated strategy to control soil-transmitted helminthiasis and clonorchiasis in the People's Republic of China. 61
32805214 2021
Innovative approaches to improve serodiagnosis of Strongyloides stercoralis infection. 61
33636109 2021
Assessment of China's contributions to the Regional Network for Asian Schistosomiasis and Other Helminth Zoonoses: a questionnaire survey. 61
33597021 2021
Prevalence, Risk Factors, and Coinfection of Urogenital Schistosomiasis and Soil-Transmitted Helminthiasis among Primary School Children in Biase, Southern Nigeria. 61
33791124 2021
Urogenital Schistosomiasis-History, Pathogenesis, and Bladder Cancer. 61
33429985 2021
Association of urogenital and intestinal parasitic infections with type 2 diabetes individuals: a comparative study. 61
33413119 2021
Prevalence and Associated Factors of Intestinal Helminths Among Kindergarten Children in Gondar Town, Northwest Ethiopia. 61
33574727 2021
Socioenvironmental Factors Influencing Distribution and Intensity of Soil-Transmitted Helminthiasis in the Brazilian Amazon: Challenges for the 2030 Agenda. 61
33613673 2021
Is there autochthonous strongyloidiasis in Spanish children? 61
33432398 2021
Description of the rare localization of Dirofilaria repens in human in the right inguinal lymph node. 61
33304811 2021
Hotspots and correlates of soil-transmitted helminth infections in a Venezuelan rural community: Which are the "wormy" houses? 61
33271168 2021
Prevalence, Infection Intensity and Associated Factors of Soil-Transmitted Helminthiasis Among School-Aged Children from Selected Districts in Northwest Ethiopia. 61
33623469 2021
Nanotechnological Improvement of Veterinary Anthelmintics. 61
32448112 2021
Evaluation of Commercially Available Anthelminthics in Laboratory Models of Human Intestinal Nematode Infections. 61
33410658 2021
Exploiting the potential of 2D DIGE and 2DE immunoblotting for comparative analysis of crude extract of Trichinella britovi and Trichinella spiralis muscle larvae proteomes. 61
33278763 2021
Human toxocariasis, a silent helminthic disease revealed in Savannakhet, Lao PDR. 61
33392380 2020
Chemical composition and broad-spectrum anthelmintic activity of a cultivar of toothache plant, Acmella oleracea, from Mizoram, India. 61
32401104 2020
Treatment efficacy and re-infection rates of soil-transmitted helminths following mebendazole treatment in schoolchildren, Northwest Ethiopia. 61
33292853 2020
Integration of health education intervention to improve the compliance to mass drug administration for soil-transmitted helminths infection in Bangladesh: An implementation research. 61
32775707 2020
Patterns of individual non-treatment during multiple rounds of mass drug administration for control of soil-transmitted helminths in the TUMIKIA trial, Kenya: a secondary longitudinal analysis. 61
33069302 2020
Comparison of real-time PCR and the Kato-Katz method for the diagnosis of soil-transmitted helminthiasis and assessment of cure in a randomized controlled trial. 61
33008301 2020
Performance of the Kato-Katz method and real time polymerase chain reaction for the diagnosis of soil-transmitted helminthiasis in the framework of a randomised controlled trial: treatment efficacy and day-to-day variation. 61
33059756 2020
Systemic profile of immune factors in an elderly Italian population affected by chronic strongyloidiasis. 61
33059754 2020
Historical analysis of inverse correlation between soil-transmitted helminthiasis and pancreatic cancer. 61
33678958 2020
Loop-Mediated Isothermal Amplification as Point-of-Care Diagnosis for Neglected Parasitic Infections. 61
33126446 2020
Prevalence, intensity and associated risk factors of soil-transmitted helminth and schistosome infections in Kenya: Impact assessment after five rounds of mass drug administration in Kenya. 61
33027264 2020
Cytotoxic and apoptotic inducing activity of Amoora rohituka leaf extracts in human breast cancer cells. 61
30846274 2020
A first nation-wide assessment of soil-transmitted helminthiasis in Fijian primary schools, and factors associated with the infection, using a lymphatic filariasis transmission assessment survey as surveillance platform. 61
32976499 2020
Role of Anti-Inflammatory, Reactive Oxygen Species Scavenging Activity and Nematicidal Properties of Myrtle Berry Seeds on Helminthiasis Treatment. 61
32986497 2020
The impact of Worms and Ladders, an innovative health educational board game on Soil-Transmitted Helminthiasis control in Abeokuta, Southwest Nigeria. 61
32976501 2020
Drug discovery technologies: Caenorhabditis elegans as a model for anthelmintic therapeutics. 61
32166776 2020
Contrasting serum biomarker profiles in two Colombian populations with different risks for progression of premalignant gastric lesions during chronic Helicobacter pylori infection. 61
32447242 2020
Effectiveness of Strongyloides Recombinant IgG Immunoreactive Antigen in Detecting IgG and IgG4 Subclass Antibodies for Diagnosis of Human Strongyloidiasis Using Rapid Immunochromatographic Tests. 61
32825495 2020
Comparison of World Health Organization and Demographic and Health Surveys data to estimate sub-national deworming coverage in pre-school aged children. 61
32804925 2020
Clinical helminthiases in Thailand border regions show elevated prevalence levels using qPCR diagnostics combined with traditional microscopic methods. 61
32787935 2020
Artemisia absinthium L.-Importance in the History of Medicine, the Latest Advances in Phytochemistry and Therapeutical, Cosmetological and Culinary Uses. 61
32825178 2020
Soil-transmitted helminthiasis: A neglected tropical disease among urban slum dwelling school-aged children of a sub-Saharan African city. 61
32687117 2020
Ethnobotanical survey, anthelmintic effects and cytotoxicity of plants used for treatment of helminthiasis in the Central and Kara regions of Togo. 61
32635909 2020
Association between the socioeconomic determinants and soil-transmitted helminthiasis among school-going children in a rural area of Haryana. 61
33102355 2020
FDA-Approved Antiparasitic Drugs in the 21st Century: A Success for Helminthiasis? 61
32387059 2020

Variations for Parasitic Helminthiasis Infectious Disease

Expression for Parasitic Helminthiasis Infectious Disease

Search GEO for disease gene expression data for Parasitic Helminthiasis Infectious Disease.

Pathways for Parasitic Helminthiasis Infectious Disease

Pathways related to Parasitic Helminthiasis Infectious Disease according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
13.76 STAT6 IL9 IL5 IL4 IL17A IL13
Show member pathways
13.62 TSLP IL9 IL5 IL4 IL33 IL17A
Show member pathways
13.47 STAT6 IL9 IL5 IL4 IL17A IL13
Show member pathways
13.37 STAT6 IL9 IL5 IL4 IL17A IL13
Show member pathways
13.31 STAT6 IL9 IL5 IL4 IL33 IL17A
Show member pathways
13.24 IL9 IL5 IL4 IL17A IL13 IL10
Show member pathways
12.76 RNASE3 IL9 IL5 IL4 IL17A IL13
Show member pathways
12.58 IL9 IL5 IL4 IL17A IL10 CD4
Show member pathways
12.56 STAT6 IL5 IL4 IL17A IL13 IL10
Show member pathways
12.37 TSLP STAT6 IL9 IL5 IL4 IL13
Show member pathways
12.25 IL5 IL4 IL17A IL13
Show member pathways
12.22 IL9 IL5 IL4 IL17A IL13 IL10
14 11.96 IL5 IL4 IL10 CD4
15 11.95 STAT6 IL4 IL17A IL13 IL10
Show member pathways
11.78 IL4 IL17A CD4
17 11.73 IL5 IL4 IL13
Show member pathways
11.68 IL17A IL10 CD4
19 11.67 IL5 IL4 IL10 ICOSLG CCR6
20 11.66 STAT6 IL9 IL4
21 11.62 STAT6 IL5 IL4 IL10
22 11.59 IL5 IL4 IL13
23 11.47 IL4 IL13 IL10
24 11.23 TSLP IL9 IL5 IL4 IL33 IL17A
25 11.22 STAT6 IL9 IL5 IL4 IL33 IL13
26 11.2 TSLP IL9 IL5 IL4 IL33 IL17A
27 11.18 IL5 IL4 IL13 IL10 CD4
28 11.07 IL9 IL5 IL4 IL13 IL10
29 10.98 IL9 IL5 IL4 IL17A IL13 IL10
30 10.78 IL9 IL5 IL4 IL13

GO Terms for Parasitic Helminthiasis Infectious Disease

Cellular components related to Parasitic Helminthiasis Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 TSLP SERPINA3 RNASE3 IL9 IL5 IL4
2 external side of plasma membrane GO:0009897 9.55 IL17A IL13 ICOSLG CD4 CCR6
3 extracellular space GO:0005615 9.36 TSLP SERPINA3 RNASE3 MIR21 IL9 IL5

Biological processes related to Parasitic Helminthiasis Infectious Disease according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.97 SERPINA3 IL9 IL5 IL17A IL13
2 positive regulation of interleukin-6 production GO:0032755 9.77 TSLP IL33 IL17A
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 TSLP IL4 IL13
4 immune response GO:0006955 9.76 IL9 IL5 IL4 IL17A IL13 IL10
5 positive regulation of cytokine production GO:0001819 9.74 MIR21 IL33 IL10
6 defense response to Gram-negative bacterium GO:0050829 9.73 TSLP RNASE3 IL17A CD4
7 T cell activation GO:0042110 9.72 IL4 ICOSLG CD4
8 positive regulation of B cell proliferation GO:0030890 9.71 IL5 IL4 IL13
9 positive regulation of interleukin-10 production GO:0032733 9.7 TSLP IL4 IL13
10 negative regulation of endothelial cell apoptotic process GO:2000352 9.69 IL4 IL13 IL10
11 positive regulation of mast cell degranulation GO:0043306 9.58 IL4 IL13
12 positive regulation of macrophage activation GO:0043032 9.58 IL33 IL13 IL10
13 type 2 immune response GO:0042092 9.56 IL4 IL10
14 positive regulation of MHC class II biosynthetic process GO:0045348 9.54 IL4 IL33 IL10
15 positive regulation of interleukin-13 production GO:0032736 9.5 TSLP IL4 IL33
16 cytokine-mediated signaling pathway GO:0019221 9.5 STAT6 IL5 IL4 IL17A IL13 IL10
17 negative regulation of complement-dependent cytotoxicity GO:1903660 9.49 IL4 IL13
18 positive regulation of isotype switching to IgE isotypes GO:0048295 9.48 STAT6 IL4
19 regulation of isotype switching GO:0045191 9.46 IL4 IL10
20 positive regulation of interleukin-5 production GO:0032754 9.43 TSLP IL9 IL33
21 positive regulation of immunoglobulin production GO:0002639 8.92 IL5 IL33 IL13 IL10

Molecular functions related to Parasitic Helminthiasis Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 IL9 IL5 IL4 IL10
2 cytokine activity GO:0005125 9.23 TSLP IL9 IL5 IL4 IL33 IL17A
3 cytokine receptor binding GO:0005126 9.13 IL9 IL4 IL13

Sources for Parasitic Helminthiasis Infectious Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....